NeoStem is developing therapeutics that target cancer initiating cells, starting with a Phase 3 trial for melanoma.
Enhancingthe body’s healing response
Rebalancingthe immune system
Unlockingthe power of VSELs
NeoStem is exploring the therapeutic potential of very small embryonic-like stem cells (VSELsTM) to regenerate or repair damaged or diseased tissues.
NeoStem’s Investigational Targeted Cancer Immunotherapy For Late Stage Melanoma (2 minute)
See how NeoStem's Phase III investigational targeted cancer immunotherapy, NBS20 (eltrapuldencel-T), is created and administered. The product candidate is being evaluated for the treatment of patients suffering from late stage malignant melanoma.
News + EventsNeoStem CSO Dr. Robert Preti Elected Vice Chairman of the Alliance for Regenerative Medicine November 25, 2014 - Learn MoreNeoStem Provides Further Information Regarding the Design of the Phase 2 PreSERVE AMI Clinical Trial November 21, 2014 - Learn MoreInvestor Call on PreSERVE AMI Phase 2 Data November 18, 2014 - Learn More
As the Chief Visionary Officer and a Director of NeoStem, and as one of the inventors of the core technolog.... Read More